127 related articles for article (PubMed ID: 11114736)
1. Ligand discrimination by ErbB receptors: differential signaling through differential phosphorylation site usage.
Sweeney C; Carraway KL
Oncogene; 2000 Nov; 19(49):5568-73. PubMed ID: 11114736
[TBL] [Abstract][Full Text] [Related]
2. Bivalence of EGF-like ligands drives the ErbB signaling network.
Tzahar E; Pinkas-Kramarski R; Moyer JD; Klapper LN; Alroy I; Levkowitz G; Shelly M; Henis S; Eisenstein M; Ratzkin BJ; Sela M; Andrews GC; Yarden Y
EMBO J; 1997 Aug; 16(16):4938-50. PubMed ID: 9305636
[TBL] [Abstract][Full Text] [Related]
3. Signal transduction and oncogenesis by ErbB/HER receptors.
Marmor MD; Skaria KB; Yarden Y
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):903-13. PubMed ID: 14967450
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor (EGFR) signaling in cancer.
Normanno N; De Luca A; Bianco C; Strizzi L; Mancino M; Maiello MR; Carotenuto A; De Feo G; Caponigro F; Salomon DS
Gene; 2006 Jan; 366(1):2-16. PubMed ID: 16377102
[TBL] [Abstract][Full Text] [Related]
6. Control of ErbB signaling through metalloprotease mediated ectodomain shedding of EGF-like factors.
Sanderson MP; Dempsey PJ; Dunbar AJ
Growth Factors; 2006 Jun; 24(2):121-36. PubMed ID: 16801132
[TBL] [Abstract][Full Text] [Related]
7. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
Huang Y; Li X; Jiang J; Frank SJ
Oncogene; 2006 Dec; 25(58):7565-76. PubMed ID: 16785991
[TBL] [Abstract][Full Text] [Related]
8. Role of HER receptors family in development and differentiation.
Casalini P; Iorio MV; Galmozzi E; Ménard S
J Cell Physiol; 2004 Sep; 200(3):343-50. PubMed ID: 15254961
[TBL] [Abstract][Full Text] [Related]
9. Ligand-independent oncogenic transformation by the EGF receptor requires kinase domain catalytic activity.
Danielsen AJ; Maihle NJ
Exp Cell Res; 2002 Apr; 275(1):9-16. PubMed ID: 11925101
[TBL] [Abstract][Full Text] [Related]
10. Growth factor receptors: structure, mechanism, and drug discovery.
McInnes C; Sykes BD
Biopolymers; 1997; 43(5):339-66. PubMed ID: 9566117
[TBL] [Abstract][Full Text] [Related]
11. An unexpected biochemical and functional interaction between gp130 and the EGF receptor family in breast cancer cells.
Grant SL; Hammacher A; Douglas AM; Goss GA; Mansfield RK; Heath JK; Begley CG
Oncogene; 2002 Jan; 21(3):460-74. PubMed ID: 11821958
[TBL] [Abstract][Full Text] [Related]
12. Grb2 regulation of the actin-based cytoskeleton is required for ligand-independent EGF receptor-mediated oncogenesis.
Boerner JL; Danielsen AJ; Lovejoy CA; Wang Z; Juneja SC; Faupel-Badger JM; Darce JR; Maihle NJ
Oncogene; 2003 Oct; 22(43):6679-89. PubMed ID: 14555981
[TBL] [Abstract][Full Text] [Related]
13. The ErbB signaling network is coordinately expressed and activated in the mouse prostate.
Zhu Y; Jones FE
Prostate; 2004 Jun; 60(1):68-75. PubMed ID: 15129431
[TBL] [Abstract][Full Text] [Related]
14. Stimulation of mitogenic pathways through kinase-impaired mutants of the epidermal growth factor receptor.
Ewald JA; Coker KJ; Price JO; Staros JV; Guyer CA
Exp Cell Res; 2001 Aug; 268(2):262-73. PubMed ID: 11478852
[TBL] [Abstract][Full Text] [Related]
15. Membrane-anchored growth factors, the epidermal growth factor family: beyond receptor ligands.
Higashiyama S; Iwabuki H; Morimoto C; Hieda M; Inoue H; Matsushita N
Cancer Sci; 2008 Feb; 99(2):214-20. PubMed ID: 18271917
[TBL] [Abstract][Full Text] [Related]
16. Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.
Maegawa M; Takeuchi K; Funakoshi E; Kawasaki K; Nishio K; Shimizu N; Ito F
Mol Cancer Res; 2007 Apr; 5(4):393-401. PubMed ID: 17426253
[TBL] [Abstract][Full Text] [Related]
17. Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor.
Witters L; Scherle P; Friedman S; Fridman J; Caulder E; Newton R; Lipton A
Cancer Res; 2008 Sep; 68(17):7083-9. PubMed ID: 18757423
[TBL] [Abstract][Full Text] [Related]
18. Controlled activation of ErbB1/ErbB2 heterodimers promote invasion of three-dimensional organized epithelia in an ErbB1-dependent manner: implications for progression of ErbB2-overexpressing tumors.
Zhan L; Xiang B; Muthuswamy SK
Cancer Res; 2006 May; 66(10):5201-8. PubMed ID: 16707444
[TBL] [Abstract][Full Text] [Related]
19. Radiotherapy-induced signal transduction.
Yacoub A; Miller A; Caron RW; Qiao L; Curiel DA; Fisher PB; Hagan MP; Grant S; Dent P
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S99-114. PubMed ID: 17259563
[TBL] [Abstract][Full Text] [Related]
20. Differential distributions of peptides in the epidermal growth factor family and phosphorylation of ErbB 1 receptor in adult rat brain.
Piao YS; Iwakura Y; Takei N; Nawa H
Neurosci Lett; 2005 Dec; 390(1):21-4. PubMed ID: 16129559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
